Drugs / Perflubutane

Trials 19 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 03 trials
Phase 0 NCT05105087 Apr 2022 → Nov 2023 cervical carcinoma, vaginal carcinoma, vulvar carcinoma Thomas Jefferson University Completed No outcome recorded
Phase 0 NCT03578224 Sep 2018 → Aug 2022 esophageal disorder Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University Completed No outcome recorded
Phase 0 NCT03009266 Jul 2018 → Dec 2019 myocardial ischemia Oregon Health and Science University Unknown No outcome recorded
Phase 13 trials
Phase 1 NCT02968680 Apr 2017 → Jun 2019 cutaneous melanoma University of Southern California Terminated No outcome recorded
Phase 1 NCT03340870 Oct → Nov 2014 GE Healthcare Completed No outcome recorded
Phase 1 NCT00156780 Aug 2004 → Jul 2005 chronic obstructive pulmonary disease, congestive heart failure Acusphere Completed No outcome recorded
Phase 1/21 trial
Phase 1/2 NCT02652923 Jan 2016 → Jan 2022 breast cancer Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University Completed No outcome recorded
Phase 23 trials
Phase 2 NCT02733029 May 2018 → May 2022 transplant rejection Brigham and Women's Hospital Completed No outcome recorded
Phase 2 NCT03245255 Dec 2017 → Sep 2020 heart failure Thomas Jefferson University Completed No outcome recorded
Phase 2 NCT02398266 Aug 2016 → Jul 2018 peripheral arterial disease Oregon Health and Science University Unknown No outcome recorded
Phase 2/31 trial
Phase 2/3 NCT07310758 Sep 2025 → Sep 2026 expected breast cancer, head and neck cancer, melanoma The Netherlands Cancer Institute Recruiting No outcome recorded
Phase 35 trials
Phase 3 NCT05470205 Nov 2022 → Feb 2026 overdue portal hypertension Thomas Jefferson University Recruiting No outcome recorded
Phase 3 NCT04006275 Jun → Dec 2019 cirrhosis of liver, hepatocellular carcinoma Second Affiliated Hospital, School of Medicine, Zhejiang University Unknown No outcome recorded
Phase 3 NCT02651090 Oct 2017 → Mar 2018 Northeastern Ohio Radiology Research and Education Fund Withdrawn No outcome recorded
Phase 3 NCT03335566 May 2014 → Apr 2015 liver disorder GE Healthcare Completed No outcome recorded
Phase 3 NCT00669851 Nov 2006 → Mar 2007 coronary artery disorder Acusphere Completed No outcome recorded
Phase 41 trial
Phase 4 NCT02489045 Apr 2015 → Mar 2019 portal hypertension Thomas Jefferson University Completed No outcome recorded
Phase not applicable2 trials
NCT05068076 Oct → Dec 2021 hepatocellular carcinoma Institute of Liver and Biliary Sciences, India Completed No outcome recorded
NCT02737865 May 2016 → Apr 2019 focal nodular hyperplasia Samsung Medical Center Completed No outcome recorded

Press releases naming this drug 3 releases

DateIssuerRelease
2012-08-10 Daiichi Sankyo Approval of Additional Indication of Ultrasound Contrast Agent SONAZOID(R) for Injection daiichisankyo.com
2007-01-10 Daiichi Sankyo Ultrasound Contrast Agent Sonazoid(R) for Injection Released for Sale daiichisankyo.com
2006-10-26 Daiichi Sankyo Ultrasound Contrast Medium Sonazoid ® Gets Import Approval daiichisankyo.com

Evidence & citations 8 cited values

Every value below carries the sentence it was read from. 20 sources stand behind the page.

FieldValueCited text
Known as Perflubutane “Sonazoid (Perflubutane)” NCT03578224
1

NCT02652923

Known as AI-700 ClinicalTrials.gov intervention name — accepted as the source's own label NCT00669851
1

NCT00156780

Known as Perflubutane Microbubble ClinicalTrials.gov intervention name — accepted as the source's own label NCT05105087
Known as Perflubutano ChEMBL registry synonym — accepted as the source's own label CHEMBL2104979
Known as Perfluorobutane ClinicalTrials.gov intervention name — accepted as the source's own label NCT05068076
Known as Sonazoid ClinicalTrials.gov intervention name — accepted as the source's own label NCT03578224
13

NCT03340870

NCT03335566

NCT03009266

NCT02733029

NCT05470205

NCT03245255

NCT04006275

NCT02489045

NCT07310758

NCT02737865

NCT02968680

NCT02651090

NCT02398266

Modality Diagnostic / imaging agent “microbubble contrast agent” NCT02398266
Route Intravenous “administered per package insert (intravenously as a continuous infusion)” NCT02733029